A comparison of fatigue in two groups of cancer patients administered or not administered carnitine after the cisplatin administration: A non-blinded, randomized controlled study

A comparison of fatigue in two groups of cancer patients administered or not administered carnitine after the cisplatin administration: A non-blinded, randomized controlled study - The study about fatigue mitigation after the cisplatin administration in cancer patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017660

Enrollment

Registered

2015-06-01

Start date

2015-07-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients who will receive chemotherapy including cisplatin (The target will be all types of tumors.)

Interventions

Intervention group Day1: Levocarnitine injection 3000mg/day Day2-7: Levocarnitine oral solution 3000mg/day Control group An individual patient receives the best and standard treatment, selected b

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Cancer patients who will receive chemotherapy including cisplatine 2)PS(ECOG)0-1 3)Patients who agree with the documents 4)Patient ages at the point of agreement is under 75 years old

Exclusion criteria

Exclusion criteria: 1)Prognosis less than 3 months 2)Hemoglobin < 10g/dL 3)Less than one month after operation or radiotherapy 4)Ineligible judged by physician other than above

Design outcomes

Primary

Measure	Time frame
Carnitine concentrations in plasma and urine Fatigue scale (FACIT-F)	—

Countries

Japan

Contacts

Public ContactTatsuhiko Kashii

Toyama University Hospital Department of Medical Oncology

tkashii@med.u-toyama.ac.jp076-434-7808

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026